Pulmonary Nocardiosis in a Multiple Myeloma Patient Treated with Proteasome Inhibitors

被引:5
|
作者
Mendonca, Nikolai P. [1 ]
Kadayakkara, Deepak K. [1 ]
Forde, Inga C. [1 ]
Rudkovaskaia, Anastasiia [1 ]
Saul, Zane K. [1 ]
Lobo, David J. [1 ]
机构
[1] Bridgeport Hosp, Yale New Haven Hlth, Dept Internal Med, Bridgeport, CT USA
来源
关键词
Lymphopenia; Multiple Myeloma; Nocardia; Proteasome Inhibitors;
D O I
10.12659/AJCR.896280
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective: Rare co-existance of disease or pathology Background: The use of proteasome inhibitors like Bortezomib to treat multiple myeloma has been associated with increased rates of opportunistic infections, including Nocardia, especially when lymphopenia is present. The prevalence or association of such infections with newer agents like Carfilzomib is not known. Case Report: A 71-year-old man with multiple myeloma presented with a 6-week history of respiratory symptoms and cyclic fevers. He was undergoing chemotherapy with Carfilzomib. Work-up revealed severe lymphopenia and a CT chest showed multiple lung nodules and a mass-like consolidation. He underwent a bronchoscopy, and respiratory cultures grew Nocardia species. He responded well to intravenous antibiotics with resolution of symptoms and CT findings. Conclusions: With the introduction of newer agents like Carfilzomib for the treatment of multiple myeloma, clinicians must maintain a high degree of suspicion for opportunistic infections to achieve early diagnosis and treatment.
引用
收藏
页码:76 / 78
页数:3
相关论文
共 50 条
  • [31] Nonselective proteasome inhibitors in multiple myeloma and future perspectives
    Gavriatopoulou, Maria
    Malandrakis, Panagiotis
    Ntanasis-Stathopoulos, Ioannis
    Dimopoulos, Meletios Athanasios
    EXPERT OPINION ON PHARMACOTHERAPY, 2022, 23 (03) : 335 - 347
  • [32] New orally active proteasome inhibitors in multiple myeloma
    Allegra, Alessandro
    Alonci, Andrea
    Gerace, Demetrio
    Russo, Sabina
    Innao, Vanessa
    Calabro, Laura
    Musolino, Caterina
    LEUKEMIA RESEARCH, 2014, 38 (01) : 1 - 9
  • [33] Why Proteasome Inhibitors Cannot ERADicate Multiple Myeloma
    Orlowski, Robert Z.
    CANCER CELL, 2013, 24 (03) : 275 - 277
  • [34] Proteasome inhibitors in multiple myeloma: 10 years later
    Moreau, Philippe
    Richardson, Paul G.
    Cavo, Michele
    Orlowski, Robert Z.
    San Miguel, Jesus F.
    Palumbo, Antonio
    Harousseau, Jean-Luc
    BLOOD, 2012, 120 (05) : 947 - 959
  • [35] Clinical Use of Proteasome Inhibitors in the Treatment of Multiple Myeloma
    Merin, Noah M.
    Kelly, Kevin R.
    PHARMACEUTICALS, 2015, 8 (01) : 1 - 20
  • [36] Pharmacodynamics and pharmacokinetics of proteasome inhibitors for the treatment of multiple myeloma
    Baljevic, Muhamed
    Orlowski, Robert Z.
    EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY, 2019, 15 (06) : 459 - 473
  • [37] Cardiovascular Toxicity of Proteasome Inhibitors in Multiple Myeloma Therapy
    Zheng, Yi
    Huang, Shan
    Xie, Bingxin
    Zhang, Nan
    Liu, Zhiqiang
    Tse, Gary
    Liu, Tong
    CURRENT PROBLEMS IN CARDIOLOGY, 2023, 48 (03)
  • [38] Old and new generation proteasome inhibitors in multiple myeloma
    Montefusco, Vittorio
    Mussetti, Alberto
    Salas, Maria Q.
    Martinelli, Giovanni
    Cerchione, Claudio
    PANMINERVA MEDICA, 2020, 62 (04) : 193 - 206
  • [39] Cardiovascular effects of multiple myeloma therapy with proteasome inhibitors
    Gavazzoni, M.
    Gorga, E.
    Vizzardi, E.
    Raddino, R.
    VASCULAR PHARMACOLOGY, 2018, 103 : 70 - 70
  • [40] IMMUNOMODULATORY AGENTS AND PROTEASOME INHIBITORS IN THE TREATMENT OF MULTIPLE MYELOMA
    Noonan, Kimberly
    Colson, Kathleen
    SEMINARS IN ONCOLOGY NURSING, 2017, 33 (03) : 279 - 291